Last €7.36 EUR
Change Today +0.246 / 3.46%
Volume 14.4K
As of 1:35 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (APS) Snapshot

Open
€6.94
Previous Close
€7.11
Day High
€7.39
Day Low
€6.94
52 Week High
02/26/15 - €7.39
52 Week Low
07/18/14 - €3.62
Market Cap
1.4B
Average Volume 10 Days
10.0K
EPS TTM
--
Shares Outstanding
187.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARIAD PHARMACEUTICALS INC (APS)

ariad pharmaceuticals inc (APS) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (APS) Details

ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Founded in 1991

ariad pharmaceuticals inc (APS) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $749.8K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $465.4K
President of Research & Development and Chief...
Total Annual Compensation: $492.4K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $427.3K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $386.4K
Compensation as of Fiscal Year 2013.

ariad pharmaceuticals inc (APS) Key Developments

Ariad Pharmaceuticals Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Financial Guidance for 2015

Ariad Pharmaceuticals Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss for the fourth quarter ended December 31, 2014 was $5.7 million, or $0.03 per share, compared to a net loss of $74.2 million, or $0.40 per share, for the same period in 2013. The decrease in net loss is primarily due to the $50 million received from Bellicum in the fourth quarter of 2014, an increase of $13.2 million in Iclusig product revenue and a decrease in operating expenses of $8.0 million, reflecting lower research and development (R&D) expenses, offset in part by an increase in interest expense of $3.8 million due to its convertible debt issuance in June 2014. Net product revenues from sales of Iclusig were $21.4 million for the quarter ended December 31, 2014 and $55.7 million for the year ended December 31, 2014. Net product revenues for the fourth quarter include Iclusig revenues of $17.0 million in the U.S. and $4.4 million in Europe. Net product revenues in the fourth quarter represented a 47% increase from the prior quarter. For the year, the company reported net loss for the full year 2014 was $162.6 million, or $0.87 per share, compared to a net loss of $274.2 million, or $1.49 per share, for the full year 2013. For 2015, the company expected net product revenues from sales of Iclusig are expected to be in the range of $130 million to $140 million. R&D expenses are expected to be in the range of $185 million to $195 million, reflecting increased development activities for Iclusig, brigatinib, and AP32788, as well as ongoing discovery research efforts. Cash and cash equivalents at December 31, 2015 is expected to be at least $200 million.

Ariad Pharmaceuticals Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 08:00 AM

Ariad Pharmaceuticals Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 08:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Harvey J. Berger, Principal Founder, Chairman, Chief Executive Officer, President and Chairman of Executive Committee.

Ariad Pharmaceuticals Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM

Ariad Pharmaceuticals Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Harvey J. Berger, Principal Founder, Chairman, Chief Executive Officer, President and Chairman of Executive Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APS:GR €7.36 EUR +0.246

APS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.75 USD +0.04
Array BioPharma Inc $8.11 USD -0.01
Evotec AG €3.83 EUR +0.057
Insys Therapeutics Inc $60.71 USD +3.26
Pfizer Ltd/India 1,989 INR -28.75
View Industry Companies
 

Industry Analysis

APS

Industry Average

Valuation APS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.3x
Price/Book 18.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit www.ariad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.